Future of the Prevention and Treatment of Coronary Artery Disease
- 1 January 2016
- journal article
- review article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 80 (5) , 1067-1072
Abstract
With ongoing progress in the prevention and treatment of coronary artery disease (CAD), a continued decrease in prevalence and lethality is expected in high-income countries. Prevention will include lipid-lowering, antithrombotic and anti-inflammatory therapies. With respect to the former, potent, safe and prolonged drugs (such as generic forms of PCSK9 inhibitors relying on monoclonal antibodies or miRNA) should result in a decreased incidence of acute coronary syndromes. Another key aspect will be the ability to identify genetic predictors of CAD and therefore implement targeted personalized prevention early in life. Curative treatment will involve a short course of potent and reversible antithrombotics, but long-term therapy will rely on the ability to stabilize or even regress plaque (eg, using PCSK9 inhibition or modified high-density lipoprotein infusions or anti-inflammatory therapies). Antithrombotic therapy will rely on highly reversible agents (or agents with specific titratable antagonists), and on personalized therapies in which the doses, combinations and duration of therapy will be determined differentially for each patient on the basis of clinical characteristics, genetic profiling and biomarkers. Finally, the need for revascularization in stable CAD will be rare, given the expected progress in prevention. The main challenge, 20 years from now, is likely to be the provision of such effective care at acceptable costs in low- and middle-income countries. (Circ J 2016; 80: 1067-1072).Keywords
This publication has 33 references indexed in Scilit:
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- β-Blockers and Cardiovascular Events in Patients With and Without Myocardial InfarctionCirculation: Cardiovascular Quality and Outcomes, 2014
- Beta-Blockers in Asymptomatic Coronary Artery DiseaseJACC, 2014
- Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart DiseaseJACC, 2014
- Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failureEuropean Heart Journal, 2014
- 2013 ESC guidelines on the management of stable coronary artery diseaseEuropean Heart Journal, 2013
- β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery DiseaseJAMA, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000New England Journal of Medicine, 2007
- Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populationsThe Lancet, 1999